🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Doximity, Inc. DOCS R3KPHARMA

Healthcare · Health Information Services · United States
https://www.doximity.com
Company Profile ↓
$24.42
-61.86% 1Y
Mkt Cap$3.11B
P/E29.07
P/B4.75
52W High$75.12
52W Low$18.01
Book Value$5.09
EPS (TTM)$0.84

Company Overview

Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.2%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 22.2%.

Consistent Profit Growth

Net profit has compounded at 36.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 33.0% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 25.5%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of $644.86M (+13.1% YoY); net profit $196.05M.
  • Trailing 12 Months Year-on-year growth — revenue +7.3%, earnings -51.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 33.0%, profit CAGR 36.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:33.02%
1 Year:7.30%

Compounded Profit Growth

5 Years:36.93%
1 Year:-51.90%

Stock Price Performance

1 Year:-61.86%
6 Months:-4.20%
3 Months:+20.30%
1 Month:-10.88%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 11% of range
$18.01 $75.12
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)47.42 · Neutral
Price Performance
1M-10.88%
3M+20.30%
6M-4.20%
1Y-61.86%
Valuation vs Sector

P/E of 29.07 is above the sector median of 24.83 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 22.2%.
  • Excellent profit margin of 25.5%.
  • Compounding revenue at 33.0% over 5 years.
  • Profit CAGR of 36.9% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 67.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
29.07
Industry PE
24.83
Forward P/E
15.76
PEG Ratio
0.59
Book Value
$5.09
Price to Book
4.75
P/S
6.58
EV/EBITDA
17.63
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
33.02%
Profit 5Y
36.93%
Revenue (YoY)
7.30%
Earnings (YoY)
-51.90%

Profitability & Returns

ROCE
22.19%
ROE
17.21%
ROA
10.95%
Profit Margin
25.48%
Op Margin
21.54%
Gross Margin
88.07%
EPS (Latest Qtr)
$0.13
EPS (TTM)
$0.84

Balance Sheet & Liquidity

Debt/Equity
1.06
Quick Ratio
5.80
Current Ratio
6.08
Debt
$9.67M
Total Assets
$1.08B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.86%
Chg in Prom Hold
0.04%
FII / Inst Holding
102.95%
Chg in FII Hold
0.10%

Financial Snapshot

Enterprise Value
$3.11B
Total Revenue (TTM)
$655.57M
EBITDA
$208.40M
Free Cash Flow
$239.70M
Operating Cash Flow
$306.34M
Shares Outstanding
127.35M
Gross Margin
88.07%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 DOCS Doximity, Inc. R3KPHARMA 24.42 29.07 $3.11B 0.00% 22.19% 17.21% 33.02% 36.93%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2020Sep 2020Dec 2020Jun 2021Sep 2021Dec 2021Jun 2022Sep 2022Dec 2022Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 36.39M45.11M58.71M72.67M79.35M97.88M90.64M102.19M115.26M108.47M113.61M135.28M126.68M136.83M-138.29M145.91M168.53M185.05M145.37M156.62M
Cost of Revenue ---------------14.47M15.79M16.43M18.70M19.41M-
Gross Profit 28.51M37.66M50.84M64.68M70.40M86.79M77.56M88.97M101.74M95.32M100.85M123.09M113.13M123.16M-123.82M130.12M152.10M166.35M125.97M132.93M
Operating Expenses ---------------75.14M75.60M88.42M94.46M101.14M-
Operating Income 2.08M10.44M17.94M24.88M24.95M35.79M21.68M32.10M38.48M29.68M33.79M58.55M46.05M53.14M-48.68M54.52M63.68M71.90M24.83M33.64M
EBITDA ---------------51.51M57.31M67.15M75.89M28.96M-
Interest Expense ---------------------
Pretax Income ---------------58.39M64.15M72.94M80.80M32.12M-
Tax Provision ----------------4.06M10.83M10.88M19.24M13.01M-
Net Income 1.46M10.04M17.23M26.32M36.09M55.65M22.38M26.30M33.47M28.41M30.60M47.96M41.38M44.15M-62.46M53.32M62.06M61.56M19.11M24.32M
Diluted EPS 0.000.020.050.090.170.260.100.120.160.130.150.240.210.22-0.310.270.310.310.100.13
R&D Expense 10.04M9.87M11.41M13.24M15.46M16.23M19.02M19.10M20.52M21.93M19.96M19.95M22.57M23.24M22.42M-26.80M30.20M34.59M-38.48M

Profit & Loss (Annual)

Figures in USD.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 116.39M206.90M343.55M419.05M475.42M570.40M644.86M
Gross Profit 101.49M175.70M303.76M365.56M424.75M514.52M574.54M
Operating Income 22.16M53.30M113.54M125.11M163.88M227.80M214.92M
Net Income 29.74M50.21M154.78M112.82M147.58M223.19M196.05M
Diluted EPS 0.130.230.700.530.721.110.98
R&D Expense 32.44M43.87M62.35M80.19M81.98M93.04M130.70M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets --251.72M991.36M1.14B1.08B1.26B1.12B
Total Equity -32.94M1.14M66.74M878.59M966.12M901.40M1.08B950.84M
Cash & Equivalents --66.39M112.81M158.03M96.78M209.61M219.18M
Total Liabilities --103.52M112.76M170.77M177.98M181.68M172.85M
Current Liabilities --102.04M111.28M139.51M147.25M156.26M154.97M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 26.20M82.97M126.58M179.60M184.10M273.26M326.46M
Investing Cash Flow -13.10M-70.42M-640.57M-59.92M31.19M-29.30M147.17M
Financing Cash Flow 1.72M5.41M560.41M-74.46M-276.52M-131.14M-464.06M
Capital Expenditure -285.00K-245.00K-1.91M-1.70M-147.00K-0-0
Free Cash Flow 25.91M82.73M124.66M177.90M183.95M273.26M326.46M
Share Buybacks 02.02M2.70M85.32M280.72M120.29M431.65M

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 87.2%84.9%88.4%87.2%89.3%90.2%89.1%
Operating Margin % 19.0%25.8%33.0%29.9%34.5%39.9%33.3%
Net Margin % 25.5%24.3%45.1%26.9%31.0%39.1%30.4%
ROE % 2,617.7%75.2%17.6%11.7%16.4%20.6%20.6%
ROCE % -35.6%12.9%12.5%17.6%20.6%22.2%

Shareholding Pattern

Insiders
2.86%
Institutions
102.95%
Public Float
105.98%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 11.23% 14.31M $373.56M
2 Vanguard Portfolio Management LLC 5.02% 6.39M $166.77M
3 Vanguard Capital Management LLC 4.69% 5.98M $156.07M
4 Shaw D.E. & Co., Inc. 4.65% 5.92M $154.63M
5 Two Sigma Investments, LP 3.65% 4.65M $121.34M
6 State Street Corporation 3.31% 4.21M $109.95M
7 Goldman Sachs Group Inc 3.21% 4.09M $106.71M
8 Geode Capital Management, LLC 3.02% 3.85M $100.51M
9 Wellington Management Group, LLP 2.46% 3.14M $81.86M
10 Deutsche Bank AG 2.27% 2.89M $75.55M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for DOCS

Google News ue, 08 Sep 2026

Doximity, Inc. $DOCS Shares Sold by Carmignac Gestion - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOcWpqWXAxMzhnZlJGN2VzMlhFRkRoOWJYeDlJQzk3Q1RxVHFHX2hGaXQzRXVXQ2pUWUc0ZVYxNGhUMzQyM0Q5bURxa2VKY2lOWVFJbjNpekx4LW5pb2dITUEwd2dGYWlZZ3J1OUd4ZlZQNjN6OHhtRTRIQ2s3em9sTUZHTU84NjNBc0FGOE…

Google News ue, 08 Sep 2026

Doximity stock downgraded at Freedom Capital (DOCS:NYSE) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQZGFsU0ZIXzdjRkdMdXNoZDMwcU4tbWlPNDFfNUxXbzFKWmhwbEtzM1lwV3JRVnJWcVg5WFpGWnJPaXVVSUZBQjlJU00tWXhhWHdkZjdtallqYVp5SUJUMnVmVklPdzdOVzItRWctZEFVQS1SMkZLZlNLYWl5bWRHTjdMSnZSUQ?oc=5" t…

Google News ue, 08 Sep 2026

Doximity stock falls as Freedom Capital cuts to hold - Investing.com

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxORlJOcE93LURXaHpOQkZ0RklUN0ZvLVZSQlp2YTQzZzV4Y2ltdnBpdVo5QU51SUhxR0ZWWVphQ2EtQU12YWtVNmJ1WExxMV82a2IyRnFRSW1na190ZVQ4cFUxbmR2Y0RnTldZdmlDakRUdWFTMnZPeEkxQzVUZXlCdDBrQTBsMnpxb3A2Rk…

Google News ue, 08 Sep 2026

DOCS Looks 46.2% Undervalued on GF Value™ as Shares Slip After D - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOTFNJU01wT2JZakQwN1RXVVFib250RWtuV0VNR2FFSFF0YUdsa0Z2dXNSVWRJclIyY2ZsOFpaOVNFa0x4RzJZdVhUZ2tpX01tdGZqMEh0VWJWdXFyRW1FRUktZ3MzOWJhZDFBbnZBTzZnOFBWNjN4cEUxamZsNDNOM2dwTGNCMklDR3VCdW…

Google News Sat, 05 Sep 2026

Doximity, Inc. (DOCS) Stock Analysis: Navigating a 17.56% Potential Upside in the Healthcare Sector - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPR1RnZy0teXdBYWlwSEVORllLRWJOb3J1T0M3anBJejE1Z0xXR0JSRE1rRzU0Sy1UOHh3S2RwRy03cS1IQ2xkWFdHUk9xTEpzX2lCTHd6WEIzVnZoa1A2anVmQVQwamFrbk1neml1QXBJQmpQQ0NZZUNEV1VOb3haUlBVaGJvOXhER3Rsdz…

Google News Wed, 19 Aug 2026

Doximity (DOCS) Stock Looks Cheap On Cash Flow Yet Fair On Earnings - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNS3E4a1lVS3Q3cHVha0I2a29FcmRXSWFyWXdmUTlSOWRxNS01TEtsbm96VTlqTmpkWW0xY2VGSFBaUmd6Y2F4bXdQZEdqUWk0dXNCMkRVcUJXT3NDQ3I2aVJXZXlPU1E5TTdrQ0M5RTR3Y0FXS2g1b05NYnExUkMzeVA0T05RZVhYS0FvUz…

DOCS — Frequently Asked Questions

What is the current share price of Doximity, Inc. (DOCS)?

As of 2026-09-19 21:16 PDT, Doximity, Inc. (DOCS) trades at $24.42 on NYSE. Its 52-week range is $18.01 to $75.12.

What is the market capitalisation of DOCS?

Doximity, Inc. (DOCS) has a market capitalisation of $3.11B on NYSE.

What is the P/E ratio of DOCS?

DOCS trades at a trailing price-to-earnings (P/E) ratio of 29.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.75.

What is the return on equity (ROE) of DOCS?

DOCS has a return on equity (ROE) of 17.21%. Its return on capital employed (ROCE) is 22.19%.

Is DOCS a good stock to buy?

This page provides a data-driven analysis of Doximity, Inc. (DOCS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space